Cannabis: Patients With Bipolar Should Avoid Use
April 1, 2020
Regardless of whatever short-term benefit patients perceive from cannabis, the evidence points clearly to an association between usage and worsening course of bipolar disorder over time.
David N. Osser, MD
The Neuroprotective Effects of Lithium
February 14, 2020
Do you need help persuading patients to try lithium?
Clinical Updates From Bipolar Telehealth
December 31, 2019
There appears to be some confusion regarding the efficacy of aripiprazole in bipolar mania and depression and for preventing bipolar episodes.
Lamotrigine: Its Role in Bipolar Disorder
November 26, 2019
The good, the bad, and the efficacy of lamotrigine.
Mania and Hypomania: The Latest Thinking on Duration of Episodes and Other Features
October 29, 2019
An international task force of experts in the diagnosis and treatment of bipolar disorder was recently convened to address concerns about DSM-5 criteria, particularly the definitions of manic episodes. The DSM’s duration criteria is an area of concern.
Fasten Your Seatbelts
September 25, 2019
The evidence is clear: bipolar disorder is frequently both underdiagnosed and overdiagnosed.
Hyperthymic Temperament
September 13, 2019
Current estimates are that 4% to 5% of the population is at risk for a disorder on the bipolar spectrum. Among the patients of that spectrum are those with a disturbance of temperament in the direction of hypomania.
Sorting Out the Antidepressant “Withdrawal” Controversy
March 11, 2019
With a combined 70+ years of clinical experience, the authors discuss scenarios that represent two possible outcomes of discontinuing serotonergic antidepressants.
New Psychopharmacology Algorithms
August 5, 2015
Dr David Osser offers compelling reasons why you might want to take a look at these 7 algorithms, each of which offers actionable consultations—usually in under 2 minutes.
Top Paper of the Year: Second Generation Antipsychotics and Schizophrenia
December 11, 2010
Dr David Osser has chosen as one of the Top Papers of the Year a meta-analysis on second generation antipsychotics and the effects of these agents on patients with schizophrenia.
